Not checkedNot checked for notices yet.
Treatment of chronic hepatitis C virus infection in the near future
Hugo Cheinquer
Annals of Hepatology · 2013
doi:10.1016/s1665-2681(19)31288-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Hepatitis C virus (HCV) is currently the most important cause of cirrhosis and hepatocellular carcinoma in the Western World.1,2 Remarkably, HCV is probably the only chronic human viral infectious agent that can be completely eradicated. Indeed, the occurrence of a sustained virological response (SVR) is almost always equivalent to a cure of the infection.3-5 More importantly, SVR is a time tested surrogate marker unequivocally linked to an increase in overall survival rate and lower incidence of hepatic decompensation, hepatocellular carcinoma and need for a liver transplant.6 For the last ten years HCV treatment has remained virtually unchanged, based almost exclusively on the combination of pegylated interferon alpha (PEG-IFNα) plus ribavirin (RBV).7-10 On May 2011 a new era started in the treatment of chronic hepatitis C, with the FDA approval of telaprevir (TVR) and boceprevir (BOC). These protease inhibitors were the first direct-acting antivirals (DAAs) to be used in routine clinical practice to treat patients with chronic hepatitis C and are now considered the standard of care for HCV genotype 1.2 These DAAs increase SVR and are able to shorten therapy in a significant proportion of both treatment-naive and treatment-experienced chronic HCV infected patients.11-14 However, the extended adverse event profile and pill burden hamper their widespread clinical use. Two new anti-HCV DAA agents, simeprevir and sofosbuvir, have just submitted their phase 3 data to the FDA and will most likely enter the HCV clinical arena in 2014, with the promise of less side effects, once daily intake and a high probability of shortening therapy. MAIN HCV TARGETS FOR DIRECT-ACTING ANTIVIRAL AGENTS
Abstract licence: CC BY-NC-ND
References29
- 25.
28 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.